Weekly Intelligence No.04 — May 18–31, 2026

On April 30, the HTA Coordination Group endorsed the first Joint Clinical Assessment report in EU history — tovorafenib (Ojemda, Ipsen) for relapsed or refractory paediatric low-grade glioma. NCPE Ireland served as assessor. IQWiG Germany served as co-assessor. The endorsement came 10 days after the European Commission granted conditional marketing authorisation — well inside the 30-day statutory window.

On May 15, the G-BA initiated its orphan drug benefit assessment for Ojemda under AMNOG — the first time a product subject to a JCA enters the German system with a European clinical assessment already endorsed. How the G-BA handles the interface between the JCA and its own orphan drug procedure will set the precedent for every oncology and ATMP launch in Europe.

The second JCA is already in progress: lifileucel (Iovance Biotherapeutics), a TIL-based autologous cell therapy for advanced melanoma. HAS France is leading the assessment. Poland’s AOTMiT is co-assessing. An ATMP, assessed by France, for a US-originated cell therapy — the complexity of what the JCA system must absorb in year one is not theoretical. It is operational.

Thirteen JCAs initiated in 2025. None endorsed. In 2026, the first report took four months. The question is no longer whether the system works. It is whether it scales.

On May 18, the FDA approved baxdrostat (Baxfendy, AstraZeneca) — the first aldosterone synthase inhibitor for adults with inadequately controlled hypertension. In the Phase 3 BaxHTN trial, the 2 mg dose lowered systolic blood pressure by 15.7 mmHg — 9.8 mmHg placebo-adjusted — in patients already receiving standard-of-care antihypertensives. Available by early June 2026.

The market access question is architectural. Hypertension is generic-saturated, cost-conscious, and volume-driven. The last new mechanism — angiotensin receptor-neprilysin inhibition with sacubitril/valsartan — launched in 2015 and required years of outcomes data before payers moved. Baxdrostat enters a therapeutic area where every HTA body will ask the same question: what does an aldosterone synthase inhibitor add over existing treatment at what price? The ASMR in France, the AMNOG in Germany, the NICE appraisal — all will turn on comparative effectiveness against a generic backbone that costs pennies.

The first new antihypertensive mechanism in twenty years is a scientific achievement. Whether it is a commercial one depends entirely on the evidence strategy — and in hypertension, the bar for added value is measured in generic prices.

On May 22, the FDA granted accelerated approval to bulevirtide (Hepcludex, Gilead) — the first and only approved treatment for chronic hepatitis delta virus infection. The approval covers adults without cirrhosis or with compensated cirrhosis, with breakthrough therapy, priority review, and orphan drug designations. The Phase 3 MYR301 study demonstrated statistically significant combined virologic and biochemical response at 48 weeks.

HDV is the most severe form of viral hepatitis — co-infecting approximately 4% of people living with hepatitis B in the United States, an estimated 80,000 patients. The virus was identified in 1977. For 47 years, there was no approved pharmacological treatment. Hepcludex was already approved in the EU in 2020, making this a case where Europe led and the US followed — the inverse of the standard launch sequence. The pricing and reimbursement dynamics of an orphan-designated first-in-class treatment for a small, severe population with zero therapeutic alternatives will test every payer’s framework for unmet need.

The CHMP recommended eight new medicines for approval at its May 18–21 meeting — three non-orphan, one orphan, one biosimilar, and three generics or hybrids — plus 18 positive opinions on indication extensions.

The most strategically significant: nerandomilast (Jascayd, Boehringer Ingelheim) — a PDE4B inhibitor for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. IPF has been dominated by nintedanib (also Boehringer) and pirfenidone for a decade. Nerandomilast is the first new mechanism to enter this space with a positive CHMP opinion — and it carries dual-indication coverage for both IPF and PPF. The HTA positioning will be watched closely: how do you price a third option in a class where the first two are approaching generic competition?

Also receiving a positive opinion: alpelisib (Vijoice) for PIK3CA-related overgrowth spectrum disorders — a conditional authorisation for an ultra-rare indication that tests the boundary between oncology pricing and rare disease pricing.

CMS published the negotiated Maximum Fair Prices for the second round of IRA drug price negotiations — 15 Part D drugs with prices taking effect January 1, 2027. The discounts range from 38% to 85% off list price. Estimated savings: $12 billion per year. Beneficiary out-of-pocket savings: $685 million.

The numbers that matter most for global pricing: Ozempic, currently listed at $959 per month, negotiated to $274. Wegovy, for higher doses, negotiated to $385 per month. Pomalyst (Bristol Myers Squibb), slashed from $21,744 to $8,650 per month.

These are not voluntary discounts. They are statutory prices. And they will become the US net prices that every international reference pricing system — including the MFN framework’s own GENEROUS, GLOBE, and GUARD models — must contend with. When the US government negotiates Ozempic to $274 per month, every country that references US prices — and every country that manufactures a GLP-1 competitor — must recalculate.

The IRA negotiated prices are not a US-domestic event. They are a reference price signal that cascades through every international pricing corridor that touches the United States.

On May 18, the White House announced the expansion of TrumpRx.gov from 74 branded medications to more than 600 generics, integrating Amazon Pharmacy, Mark Cuban’s Cost Plus Drugs, and GoodRx as fulfilment and comparison partners. Common medications including atorvastatin, lisinopril, metformin, and clopidogrel are now listed — many priced under $5. Amazon Pharmacy is on track to expand same-day prescription delivery to 4,500 cities by year-end.

TrumpRx is designed for cash-paying patients who bypass insurance entirely. The structural implication is not the individual drug prices — it is the creation of a parallel pricing architecture that operates outside the PBM-insurer-manufacturer triangle. If 600 generics are transparently priced through a government portal with Amazon delivery, the pressure on brand pricing is not clinical. It is political. And in an election year, political pressure converts into regulatory pressure faster than any HTA assessment.

The Section 232 pharmaceutical tariff deadline is no longer a distant threat. As of this week, Annex III companies — the 17 largest pharmaceutical manufacturers — have 66 days until 100% ad valorem tariffs take effect on July 31, 2026, unless they have reached both an MFN pricing agreement with HHS and an onshoring plan with Commerce. All other manufacturers face the same tariff from September 29.

Companies that have signed: 0% tariffs through January 20, 2029. Companies that have not signed — including GSK, Johnson & Johnson, Pfizer, and Regeneron — face the full 100%. The tiered structure is explicit: companies with only an onshoring agreement pay 20%. Companies with only an MFN agreement pay a reduced rate. Companies with neither pay 100%.

The administration is simultaneously working with Congress to codify the voluntary MFN agreements into legislation — converting voluntary compliance into statutory obligation. The 35% decline in European launches documented by GlobalData is the industry’s first-order response. The second-order response — restructuring global supply chains around US manufacturing — is measured in years and billions.

Sixty-six days. That is the distance between the current pharmaceutical pricing architecture and a 100% tariff wall around the world’s largest market.

On May 27, the FDA extended the comment period for its real-time clinical trials RFI from May 29 to June 29 — an additional month for stakeholders to shape the design of the broader pilot programme. Final selection criteria remain on track for July, with pilot participants expected in August.

Separately, on May 13, the FDA published a second RFI — this one focused specifically on AI-enabled optimisation of early-phase clinical trials. The scope: enhanced patient selection, dose optimisation, safety monitoring, and earlier go/no-go determinations. Two parallel pilots — real-time data transmission and AI-enabled trial design — are now converging on the same timeline.

The combination is not coincidental. Real-time data flows require AI to be interpretable. AI-enabled trial optimisation requires real-time data to function. The two initiatives are architecturally complementary — and together, they represent the most significant restructuring of the FDA-sponsor relationship since electronic submissions.

The aligned MHRA–NICE pathway — launched April 1 with 27 early adopter companies — is approaching its first formal guidance, expected in June 2026. The pathway promises simultaneous delivery of marketing authorisation and NICE technology appraisal, compressing the current sequential process by three to six months.

Early signals suggest the operational reality is more complex than the headline. Integrating scientific advice across a regulator and an HTA body — one assessing benefit-risk, the other cost-effectiveness — requires alignment on evidence requirements, comparator selection, and outcome measures that have historically been negotiated separately. The June guidance will reveal whether the pathway delivers the speed it promises under real-world conditions — or whether the structural differences between regulatory and HTA evidence standards create friction that the timeline cannot absorb.

Twenty-seven companies signed up. The first guidance arrives in weeks. If it works, the UK becomes the fastest major market from approval to reimbursement. If it does not, the three-to-six-month promise becomes a case study in why regulatory and HTA alignment is harder than it sounds.

The FDA real-time trials RFI comment period now closes June 29 — one month of additional input remains. The European Commission is expected to complete procedural review of the first JCA report on tovorafenib — publication of the full report would make the clinical assessment available to all 27 member states. The MHRA–NICE first aligned pathway guidance remains on track for June. The GKV-Beitragssatzstabilisierungsgesetz continues its parliamentary progress toward the summer recess, with January 1, 2027 as the effective date for most provisions. And with 66 days to the July 31 Annex III tariff deadline, the window for non-signatories to reach MFN agreements is closing.

Share

Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients — written from inside the industry, for the people whose decisions move drugs to patients.